S. M. Robertson

发表

Lack of In Vivo Correlation Between Indinavir and Saquinavir Exposure and Cytochrome P450 3A Phenotype as Assessed with Oral Midazolam as a Phenotype Probe

E. Formentini, S. Penzak, R. Alfaro, 2006, Pharmacotherapy.

Limitations of Using a Single Postdose Midazolam Concentration to Predict CYP3A‐Mediated Drug Interactions

R. Davey, E. Formentini, S. Penzak, 2008, Journal of clinical pharmacology.

Influence of Panax ginseng on Cytochrome P450 (CYP)3A and P‐glycoprotein (P‐gp) Activity in Healthy Participants

J. Kovacs, S. Penzak, Jennifer D. Hunt, 2012, Journal of clinical pharmacology.

Are Literature References Sufficient for Dose Recommendations? An FDA Case Study of Efavirenz and Rifampin

K. Chan-Tack, K. Struble, K. Reynolds, 2008, Journal of clinical pharmacology.

Efavirenz Induces CYP2B6-Mediated Hydroxylation of Bupropion in Healthy Subjects

V. Natarajan, F. Maldarelli, E. Formentini, 2008, Journal of acquired immune deficiency syndromes.

The Role of Clinical Pharmacology in Supporting the Emergency Use Authorization of an Unapproved Anti‐Influenza Drug, Peramivir

V. Arya, S. M. Robertson, W. Carter, 2010, Clinical pharmacology and therapeutics.

Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies

E. O'Mara, M. Rogge, D. Heald, 2016, Journal of clinical pharmacology.

Chapter 15 – Drug Interactions

Shiew-Mei Huang, S. Penzak, S. M. Robertson, 2007 .

Drug interactions in the management of HIV infection: an update

S. Penzak, A. Pau, S. M. Robertson, 2007, Expert opinion on pharmacotherapy.

Drug interactions in the management of HIV infection

S. Penzak, A. Pau, S. M. Robertson, 2005, Expert opinion on pharmacotherapy.

Elevated Plasma Concentrations of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors in Patients Coinfected with Human Immunodeficiency Virus and Hepatitis B or C: Case Series and Literature Review

P. Lynch, K. Scarsi, S. M. Robertson, 2005, Pharmacotherapy.

Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.

V. Natarajan, J. Falloon, E. Formentini, 2006, British journal of clinical pharmacology.

Drug Interactions With Antiretrovirals for HIV Infection

S. Piscitelli, K. Struble, S. M. Robertson, 2011 .

Echinacea purpurea Significantly Induces Cytochrome P450 3A Activity but Does Not Alter Lopinavir‐Ritonavir Exposure in Healthy Subjects

Scott R. Penzak, J. Kovacs, S. Penzak, 2010, Pharmacotherapy.

Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects

R. Davey, E. Formentini, S. Penzak, 2008 .

A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature.

J. Mican, S. Penzak, A. Pau, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?

Jiang Liu, Jeffrey B. Kraft, K. Chan-Tack, 2014, International journal of clinical pharmacology and therapeutics.

CHAPTER 15 – Drug Interactions

S. Penzak, S. M. Robertson, 2007 .

Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.

R. Davey, E. Formentini, S. Penzak, 2008, Current medical research and opinion.